ALX Oncology Holdings ALXO 深 沪
等待开盘 08-14 09:30:00 美东时间
0.6799
+0.065
+10.53%
华盛通- 最 高0.6927
- 今 开0.62
- 成交量 50.07万股
- 最 低 0.6171
- 昨 收 0.6151
- 总市值 3633.66万
- 52周最高 2.585
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.404
- 委 比 -54.95%
- 总股本 5344.40万
- 历史最高 117.45
- 量 比 1.63
- 振 幅 12.29%
- 历史最低 0.404
- 每 手 1
- 风险率 0.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ALX Oncology Appoints Dr. Curran to Board
An announcement from ALX Oncology Holdings ( ($ALXO) ) is now available. On Aug...
08-13 04:50
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
ALX Oncology reported Q2 2025 financial results and corporate updates, highlighting advancements in their evorpacept and ALX2004 clinical programs. CD47 expression emerged as a key predictive biomarker for evorpacept response in HER2+ gastric cancer, with updated ASPEN-Breast trial design focusing on biomarker-driven strategies. The Phase 1 trial for ALX2004 remains on track, with first patient dosing expected in August. The company extended its ...
08-12 20:05
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
ALX Oncology Holdings's Earnings: A Preview
ALX Oncology Holdings (NASDAQ:ALXO) is set to give its latest quarterly earning...
08-12 02:03
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
ALX Oncology announces plans to report its Q2 2025 financial results on August 12, 2025, after market close, along with a business update. A teleconference and webcast will be held at 1:30pm PT / 4:30pm ET, accessible via phone or web. The event will include a live audio webcast with slides available on the Company's website. ALX Oncology is a clinical-stage biotech advancing novel cancer therapies, including evorpacept and ALX2004, with ongoing ...
08-05 12:00
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
ALX Oncology announced its participation in the Jefferies 2025 Global Healthcare Conference with a fireside chat scheduled for June 5, 2025, at 1:25 PM ET in New York. The webcast will be accessible via the company's website, and a replay will be available for 90 days. ALX Oncology focuses on developing innovative cancer therapies, including evorpacept and ALX2004, with ongoing clinical trials. More information is available on their website or Li...
05-30 12:00
ALX Oncology Unveils Clinical Development Plans For ALX2004, A ADC Targeting EGFR-Expressing Tumors, With Phase 1 Trials Set For Mid-2025 Following FDA IND Clearance And Initial Data Expected In 1H 2026, While Advancing CD47-Blocker Evorpacept In Breast And Colorectal Cancer Trials Also Starting Mid-2025
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by
05-20 20:10
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
HC Wainwright & Co. Maintains Buy on ALX Oncology Holdings, Lowers Price Target to $2
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and lowers the price target from $5 to $2.
05-09 19:10
